Equities Analysts Offer Predictions for NRXP FY2025 Earnings

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Equities researchers at HC Wainwright increased their FY2025 earnings estimates for NRx Pharmaceuticals in a research report issued on Thursday, March 20th. HC Wainwright analyst V. Bernardino now expects that the company will earn ($0.06) per share for the year, up from their previous estimate of ($0.07). HC Wainwright has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.75) per share.

A number of other research analysts also recently commented on the stock. Ascendiant Capital Markets increased their price objective on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. D. Boral Capital reiterated a “buy” rating and issued a $31.00 price target on shares of NRx Pharmaceuticals in a research note on Monday.

NRx Pharmaceuticals Stock Down 0.5 %

NRXP stock opened at $2.07 on Monday. The stock’s 50 day moving average is $2.77 and its two-hundred day moving average is $2.04. NRx Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $6.01. The company has a market capitalization of $35.02 million, a PE ratio of -0.97 and a beta of 1.22.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings results on Friday, March 14th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.10).

Institutional Investors Weigh In On NRx Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Sassicaia Capital Advisers LLC acquired a new stake in shares of NRx Pharmaceuticals in the fourth quarter valued at approximately $33,000. Townsquare Capital LLC bought a new position in NRx Pharmaceuticals during the third quarter valued at about $25,000. Squarepoint Ops LLC acquired a new position in NRx Pharmaceuticals in the fourth quarter worth approximately $56,000. Millennium Management LLC acquired a new stake in NRx Pharmaceuticals during the 4th quarter worth about $61,000. Finally, Anson Funds Management LP grew its holdings in shares of NRx Pharmaceuticals by 30.3% during the fourth quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock valued at $408,000 after buying an additional 43,135 shares in the last quarter. 4.27% of the stock is owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.